SCHEMBL23922254

SCHEMBL23922254

COP(=O)(CP(=O)(OCc1ccccc1)OCC1OC(n2cnc3c(N)ncnc32)C(OC(C)=O)C1OC(C)=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 3/20 0.58
P2RX4 Q99571 3/20 0.58
P2RX2 Q9UBL9 3/20 0.58
P2RX1 P51575 2/20 0.52
P2RX7 Q99572 2/20 0.52
P2RY12 Q9H244 5/20 0.51
P2RY11 Q96G91 2/20 0.51
ENPP1 P22413 2/20 0.51
P2RX6 O15547 1/20 0.51
P2RX5 Q93086 1/20 0.51
P2RY2 P41231 3/20 0.49
P2RY1 P47900 2/20 0.49
AHCY P23526 1/20 0.48
PRKAB2 O43741 2/20 0.48
PRKAG1 P54619 2/20 0.48
PRKAA2 P54646 2/20 0.48
PRKAA1 Q13131 2/20 0.48
PRKAG3 Q9UGI9 2/20 0.48
PRKAG2 Q9UGJ0 2/20 0.48
PRKAB1 Q9Y478 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23922249 0.93 P2RX3 (0.60) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL22393015 0.89 P2RX3 (0.53) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL26361369 0.87 P2RX3 (0.51) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL26937426 0.87 P2RX3 (0.51) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL23922239 0.87 P2RY1 (0.64) P2RX3P2RX4P2RX2P2RX1P2RY12
SCHEMBL22393010 0.84 P2RX3 (0.47) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL22393012 0.84 P2RX3 (0.47) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL26361444 0.83 P2RX3 (0.47) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL23922272 0.80 P2RY12 (0.56) P2RX3P2RX4P2RX2P2RX1P2RX7
SCHEMBL22393145 0.80 P2RY12 (0.56) P2RX3P2RX4P2RX2P2RX1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 US disclosed
US-20210403501-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) 2021-12-30 US disclosed
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX2 1042/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX2 1042/4885
US-20210403501-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX2 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.